Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Note real therapies don’t exclude ARDS like HGEN drug.
Real therapy with a drug designed for covid. Not some recycled HHEN drug. Not some drug that will change primary endpoint in 11th hour.
Competitor _ Sorrento with drugs designed for Covid
Sorrento Therapeutics, Inc.?(Nasdaq: SRNE, "Sorrento") announced today additional positive results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). This ongoing study (PSC-CP-004) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for three infusions for a total of 1 x 106 cells/kg. The primary objective is to evaluate the safety of intravenous infusion of allogeneic adipose MSC cells in patients with COVID-19-induced ARD or ARDS.
On January 26, 2021, Sorrento announced the first three enrolled ICU COVID-19 patients were discharged from the hospital within a week of starting COVI-MSC infusions and a fourth patient just started the COVI-MSC treatment last Monday, January 25, 2021. The fourth patient who had been in the hospital for more than 2 weeks and required intubation and mechanical ventilation with worsening pulmonary compromise received 3 infusions of COVI-MSC and improved so rapidly that he was able to be discharged the evening after his 3rd infusion on January 29, 2021. No infusion related safety events were reported. Dr. Eyad Almasri, Associate Professor of Medicine, Pulmonary, Critical Care and Sleep Medicine at UCSF Fresno, is the principal investigator in this ongoing study.
Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics, stated “It brings us great joy each time one of our treatments helps to save a life, after all that is what we at Sorrento work toward each and every day to save one life at a time.”
More information on the Phase 1 trial can be found at www.clinicaltrials.gov (NCT04486001). Information on the proposed Phase 2 trial is expected to be available soon.
Stem cells have been demonstrated to support resolution of symptoms in multiple disease settings and have the potential to reduce the long-term effects associated with pulmonary tissue damage. More information on the potential use and benefits of MSCs for patients with COVID-19 can be found in the recently published review at: https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02380-2
Personalized Stem Cells, Inc.?(PSC) is the GMP manufacturer partner for Sorrento’s COVI
Competitor company. Much better outcomes
What are the most effective therapies for treating a SARS-CoV-2 infection? Which therapies are showing promise, and which are little more than snake oil? Keeping track of treatments is tricky, with news of new vaccines and drugs breaking almost daily.
The German government has now announced it will buy 200,000 doses of bamlanivimab and REGN-CoV-2 for a total cost of €400 million ($485 million), which works out as €2,000 ($2,400) per dose. The drugs will be administered to high-risk patients. Bamlanivimab is a single antibody therapy produced by Eli Lilly. REGN-CoV-2 consists of two antibodies — casirivimab and imdevimab — and has been developed by Regeneron.
Former US President Donald Trump was treated with the latter after contracting the coronavirus in October last year. Bamlanivimab and REGN-CoV-2 both received emergency use by the US Food and Drug Administration (FDA) in November 2020. The European Union has yet to greenlight either of the therapies.
SOC has improved and that’s why this drug looks less appealing.
The same way they know which secondary endpoint might enhance their chances of success.
A price change from near $21 to $16 is a significant price drop.
Granted it’s AH. HGEN might be in a little bit of a pickle in the next month. It APPEARS the primary endpoint was not looking good for trial participants in this blinded trial or more power was needed.
Leadership matters.
AH market says it’s not good news.
Lipstick on a pig. News like this is bad news. Explains why enrollment was slow.
Robinhooders can’t trade until 9:00AM. Algorithms are going to turn to the downside.
Horrible news. Can’t change a primary endpoint now.
Nomis is going to drop some serious shares for sure.
Another buying opportunity right? Leadership put new investors out to pasture instead of waiting on results and then diluting. It appears they wanted to get in front of the Nomis selling.
Best wishes to HGEN, CYDY or any other drug in 2021. Drugs with less efficacy than moderna and Pfizer will be approved around the world.
Karma
Martin Shkreli lead this company but it doesn’t have any bearing on the success of the drug.
Ditto that Palm. There’s a need for both and many more.
Support levels $16.50, $16 and $15.70. IMO $16 looks pretty strong. End of year uncertainty of course.
But what do I know.
I agree.
She... but you probably haven’t seen a kitty Kat since one had you.
Company still sucks.
The HGEN pump continues.
One lock period ended for “bay” and the other expires around the Dec 15th. Price dropping as I suggested it would. No catalyst equals SP dissolution.
Just stating the obvious by saying reduced market potential. I didn’t say no market potential. It can go to $1,000 I don’t care. I’m diversified.
Nice SP drop. Lol. Now some potential headwinds are approaching. It might get UGLY for the longs here.
Timing, more patients needed and poor enrollment has handicapped company.
But but but JPMorgan. Lol.
Like HGEN investors would say, You miss the point. We are more upstream. Vaccines are more upstream as you can get.
95% upstream.
Lol. It’s always a short trying to protect a position. How about the more vaccines that are approved, more therapeutics improving outcomes, equates to a reduced market cap for HGEN.
Better therapies are reducing viral load.
Downgrades are coming.
Analysts will CONTINUE to downgrade HGEN’s potential stay tuned. Factor in vaccines will be hitting the market next month. Market potential is dropping daily.
Market potential for HGEN goes down every week as BP sucks the air out of the room. Regeneron and Merck this week. Those therapies are looking good.
Regeneron new therapy reduces viral load. Lenz does not.
That’s a problem compared to Regeneron.
Rumors, Humors. LOL. Markets are forward looking. Looking forward, the market says, less need for HGEN. Share price drops.
And therapies are months away. HGEN included.
Trial results are not coming until next year. Trial was already running behind the September end date. Now you are looking best case scenario trial end December and results Jan at the earliest. Another vaccine will be hitting the news before then and massive unloading of lockup shares flooding the market for tax loss selling.
Price is @$1.60 pre reverse split. Still overpriced considering some folks can’t sell yet and obviously they are not buying.
Moderna and AstraZeneca hope to have vaccine by end of year.
The additional patients needed and slow enrollment equals a falling share price for HGEN.
Lock up period will end before results are released.
More supply is coming Soon.
HGEN stock is toast. Lock up period ends and more selling on order.
At least one lock up period will expire before results will be finalized next year. Requiring more patients will continue to delay top line. This might get naaassssttttyyyyy
Garbage stock. Still.
Lol from the same person that was buying at $12, $13.
HGEN is just starting other trial after announcing it four months ago.
Looks like I’m missed? Is someone asking about this female player? Big bone slayer?